Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

References

• goldcopd.org [homepage on the Internet]. Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD2015 Available from: http://www.goldcopd.org/:2015Accessed June 24, 2015
   Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00379424214176
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200725677578917314337
   PubMed Web of Science ®Google Scholar
• CelliBFergusonGAndersonJSalmeterol/fluticasone propionate improves lung function and reduces the rate of decline over three years in the TORCH survival studyAm J Respir Crit Care Med200817833233818511702
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• WelshEJCatesCJPoolePCombination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20135CD00789123728670
   PubMed Web of Science ®Google Scholar
• ValotisAHoggerPHuman receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoateRespir Res200785417650349
   PubMed Web of Science ®Google Scholar
• KempsfordRNorrisVSiedererSVilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPDPulm Pharmacol Ther20132625626423232038
   PubMed Web of Science ®Google Scholar
• KerwinEMScott-WilsonCSanfordLA randomized trial of fluticasone furoate/vilanterol (50/25 µg; 100/25 µg) on lung function in COPDRespir Med201310756056923352226
   PubMed Web of Science ®Google Scholar
• MartinezFJBosciaJFeldmanGFluticasone furoate/vilanterol (100/25; 200/25 µg) improves lung function in COPD: a randomized trialRespir Med201310755055923332861
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomized controlled trialsLancet Respir Med2013121022324429127
   PubMed Web of Science ®Google Scholar
• DransfieldMTFeldmanGKorenblatPEfficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patientsRespir Med20141081171117924998880
   PubMed Web of Science ®Google Scholar
• AgustiAGNSystemic effects of chronic obstructive pulmonary diseaseProc Am Thorac Soc2005236737016267364
   PubMedGoogle Scholar
• JonesPWWedzichaJAAgustiABaseline demographic and clinical profile of patients with and without cardiovascular diseases in the Assessment of Comorbidities in COPD in European Symptomatic Subjects from primary care (ACCESS) studyEur Respir J201342suppl 571067s
   Google Scholar
• CurkendallSMDeLuiseCJonesJKCardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patientsAnn Epidemiol200616637016039877
   PubMed Web of Science ®Google Scholar
• FinkelsteinJChaEScharfSMChronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidityInt J Chron Obstruct Pulmon Dis2009433734919802349
   PubMedGoogle Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsCardiovascular events in patients with COPD: TORCH study resultsThorax20106571972520685748
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGDonnerCFInhaled β2-adrenoceptor agonistsDrugs2005651595161016060696
   PubMed Web of Science ®Google Scholar
• JonesPWHealth status measurement in chronic obstructive pulmonary diseaseThorax20015688088711641515
   PubMed Web of Science ®Google Scholar
• LotvallJBakkePSBjermerLEfficacy and safety of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomized trialBMJ Open20122e000370
   PubMed Web of Science ®Google Scholar
• BosciaJAPudiKKZvarichMTSanfordLSiedererKCrimCEffect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover studyClin Ther2012341655166622789766
   PubMed Web of Science ®Google Scholar
• BollmeierSGProsserTRCombination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary diseaseAnn Pharmacother20144825025724259654
   PubMed Web of Science ®Google Scholar
• AgustíAde TeresaLDe BackerWA comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPDEur Respir J20144376377224114969
   PubMed Web of Science ®Google Scholar
• DonohueJMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD assessment test: a prospective analysisLancet Respir Med2014219520324621681
   PubMed Web of Science ®Google Scholar
• JonesPWEstimation and application of the minimum clinically important difference in COPDLancet Respir Med2014216716924621674
   PubMed Web of Science ®Google Scholar
• CelliBRDecramerMLystigTKestenSTashkinDPLongitudinal inspiratory capacity changes in chronic obstructive pulmonary diseaseRespir Res2012136622866681
   PubMed Web of Science ®Google Scholar
• TaubeCLehnigkBPaaschKKirstenDKJörresRAMagnussenHFactor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016221622010903244
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPDEur Respir J2004117suppl 12A49S59S
   Google Scholar
• KewKMSeniukovichAInhaled steroids and risk of pneumonia for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20143CD01011524615270
   PubMed Web of Science ®Google Scholar
• CrimCDransfieldMTBourbeauJPneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPDAnn Am Thorac Soc201512273425490706
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• DongY-HLinH-HShauW-YWuY-CChangC-HLaiM-SComparative safety of inhaled medications in patients with chronic obstructive pulmonary: systematic review and mixed treatment comparison meta-analysis of randomized controlled trialsThorax201368485623042705
   PubMed Web of Science ®Google Scholar
• CovelliHBhattacharyaSCassinoCConoscentiCKestenSAbsence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary diseasePharmacotherapy2005251708171816305289
   PubMed Web of Science ®Google Scholar
• KestenSCelliBDecramerMLeimerITashkinDTiotropium HandiHaler® in the treatment of COPD: a safety reviewInt J Chron Obstruct Pulmon Dis2009439740920037679
   PubMedGoogle Scholar
• VerhammeKMCAfonsoASMvan NoordCHaagMDKoudstaalPJBrusselleGGOTiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPDPulm Pharmacol Ther201225192622051450
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTIOSPIR InvestigatorsTiotropium respimat inhaler and the risk of death in COPDN Engl J Med20133691491150123992515
   PubMed Web of Science ®Google Scholar
• KatritsisDEZarebaWCammAJNonsustained ventricular tachycardiaJ Am Coll Cardiol2012601993200423083773
   PubMed Web of Science ®Google Scholar
• BuxtonAEDucJBergerEETorresVNon-sustained ventricular tachycardiaCardiol Clin20001832733610849876
   PubMedGoogle Scholar
• VlachopoulosCAznaoundisKStefanadisCPrediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysisJ Am Coll Cardiol2010551318132720338492
   PubMed Web of Science ®Google Scholar
• VivodtzevITamisierRBaguetJ-PBorelJCLevyPPépinJ-LArterial stiffness in COPDChest201414586187524687708
   PubMed Web of Science ®Google Scholar
• PepinJ-LCockcroftJRMidwinterDSharmaSRubinDBAndreasSLong-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropiumChest20141461521153025058845
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJBrookRDThe study to understand mortality and morbidity in COPD (SUMMIT) study protocolEur Respir J2013411017102223018908
   PubMed Web of Science ®Google Scholar
• St CharlesMBlanchetteCMSilverHLavalleeDDalalAAMapelDAdherence to controller therapy for chronic obstructive pulmonary disease: a reviewCurr Med Res Opin2010262421242920815661
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJACalverleyPMAdherence to inhaled therapy, mortality and hospital admission in COPDThorax20096593994319703830
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105434441
   Web of Science ®Google Scholar
• GauharUDransfieldMCooperJASequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice settingInt J Chron Obstruct Pulmon Dis2009439139519888357
   PubMedGoogle Scholar
• HalpernRBakerCLSuJOutcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary diseasePatient Prefer Adherence2011537538821845037
   PubMed Web of Science ®Google Scholar
• PriceDLeeAJSimsEJCharacteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort studyPrim Care Respir J20132216116823460035
   PubMedGoogle Scholar